Through modulation of MMPs and ADAMs, RECK could target several key inflammatory and fibrogenic pathways by modulating ECM, inflammatory cytokines, and several other cellular processes, which could influence the outcomes of diseases such as NAFLD and NASH (Figure 1; key cellular targets listed in Table 1). Here, RECK is linked to metabolic dysfunction-associated steatotic liver disease.